Clinical Trials Directory

Trials / Completed

CompletedNCT04402450

Suprainguinal Fascia Iliaca Block Versus PENG Block for Hip Arthroplasty Analgesia

A Randomized Comparison Between Ultrasound-Guided Suprainguinal Fascia Iliaca Block and Pericapsular Nerve Group Block For Total Hip Replacement

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
University of Chile · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

In recent years, suprainguinal fascia iliaca block (SFIB) has emerged as a reliable analgesic option for primary total hip arthroplasty (THA). In 2018, a new block was described, termed pericapsular nerve group block or PENG block, that selectively targets the articular branches of the femoral and obturator nerves while sparing their motor components. In this randomized trial, the investigators will compare US-guided SFIB and PENG block in patients undergoing primary THA. Since the main benefit of PENGB stems from its quadriceps-sparing effect, it was selected the incidence of quadriceps motor block (at 6 hours) as the primary outcome and the hypothesis that PENG block will result in significantly less motor block compared to SFIB.

Conditions

Interventions

TypeNameDescription
PROCEDUREUltrasound-guided suprainguinal fascia iliaca nerve blockAfter an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
PROCEDUREUltrasound-guided pericapsular nerves group of the hip blockAfter an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.

Timeline

Start date
2020-08-31
Primary completion
2021-05-25
Completion
2021-05-28
First posted
2020-05-26
Last updated
2021-09-28

Locations

1 site across 1 country: Chile

Source: ClinicalTrials.gov record NCT04402450. Inclusion in this directory is not an endorsement.